Evidence map›Paper›PMID 40392159›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2025

Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging.

Ravi Kumar, Katherine Lajkosz, Ur Metser, Jimmy Misurka, Jenna Hiemstra, Jayson Kreidstein, Lauren Calicchia, Amalia Silberman, Antonio Finelli, Neil E Fleshner and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ravi KumarDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Katherine LajkoszDeptartment of Biostatistics, University of Toronto, Toronto, ON, Canada.
Ur MetserDepartment of Medical Imaging, University of Toronto, Toronto, ON, Canada.
Jimmy MisurkaDivision of Urology, Department of Surgery, University Health Network, Toronto, ON, Canada.
Jenna HiemstraDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Jayson KreidsteinDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Lauren CalicchiaDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Amalia SilbermanDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Antonio FinelliDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Neil E FleshnerDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Robert J HamiltonDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Girish S KulkarniDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Alexandre ZlottaDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Alejandro BerlinRadiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Nathan PerlisDepartment of Surgery, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe ability of prostate-specific antigen density (PSAD) to predict metastatic disease on prostate-specific membrane antigen-positron emission tomography (PSMA-PET) at initial staging in high-risk prostate cancer (PCa) for men with negative conventional imaging is unclear. We hypothesized that there might be a PSAD cutoff below which PSMA-PET would be unnecessary, as it would so rarely identify metastatic disease.

methodsA retrospective cohort study of all men receiving

resultsA total of 140 men with high-risk PCa and negative conventional imaging were included. The median age was 68 years (interquartile range [IQR] 63-74). Median PSA and PSAD were 13.9 (IQR 6.9-29.5) and 0.36 ng/ml

conclusionsIn this retrospective cohort, PSAD does not reliably predict which patients with high-risk PCa and negative conventional imaging will have metastatic disease unveiled by PSMA-PET.

Identifiers

PMID40392159
PMCPMC12453886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.